Menu
Menu
SOPHiA GENETICS is proud to announce the launch of SOPHiA DDM™ Dispatch. It represents an expansion of the SOPHiA GENTICS Integrated Solutions business area, which is a well-established model for working with partner labs to democratize data driven medicine by increasing access to next-generation sequencing and accompanying analysis. SOPHiA DDM™ Dispatch makes it even easier for partner labs to come online and operate independently.
With SOPHiA DDM™ Dispatch, our partner labs can handle orders directly with the clients, streamlining operations and improving efficiency. Dispatch enables labs to take advantage of any unused capacity and creates an additional source of samples. For clients looking for sequencing services, SOPHiA DDM™ Dispatch offers increased data visibility, data ownership and simplifies the ordering process.
With SOPHiA DDM™ Dispatch and SOPHiA GENETICS Integrated Access, client institutions can get access to powerful insights without the setup costs. Clients send their samples to partner labs for sequencing, then the sequencing data is delivered to the institutions in their SOPHiA DDM™ account. This gives growing institutions better access to accurate analysis and allows them to retain ownership of their sequencing data. SOPHiA DDM™ Dispatch and SOPHiA GENETICS Integrated Access offer institutions more than just a report, by combining raw data ownership and ongoing access to powerful tertiary analysis.
Partner labs can easily begin offering service through either Integrated Solutions model, offering an opportunity to gain an additional revenue stream. Partner labs control the testing menu they offer and do not have to do data interpretation, since clients are enabled to do interpretation through SOPHiA DDM™. Furthermore, new tests can be seamlessly incorporated into your existing workflow.
Explore how the SOPHiA DDM™ Platform can help your institution today.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.